-
Bora Pharmaceuticals collaborates with Taishin Holdings to launch CDMO investment and M&A plan
prnasia
December 09, 2021
Bobby Sheng, chairman of Bora Pharmaceuticals (6472.TWO), today announced a partnership with Taishin Healthcare Limited Partnership at the 2021 Biotech Investor Forum...
-
KYOWA, Bora Pharmaceuticals Enter Mfg. Pact
contractpharma
August 11, 2021
Upon approval in Japan, Bora will be the commercial manufacturing site for the generic product production.
-
KYOWA Pharmaceutical Industry Co. Ltd. Partners with Bora Pharmaceuticals to Manufacture Generic Product for Filing in Japan
prnasia
August 05, 2021
KYOWA Pharmaceutical Industry Co. Ltd., a premier Japanese pharmaceutical company, has contracted with Bora Pharmaceutical Laboratories Inc. (Zhunan), a division of Bora Pharmaceuticals for the manufacturing of generic product for filing in Japan.
-
Bora Group announce the rebranding of Yuta Health to Bora Health
prnasia
July 06, 2021
Leading Taiwan, China-based contract development and manufacturing organization (CDMO) Bora Group today announced a name change for its subsidiary, currently Yuta Health, to Bora Health Inc. as part of an overall plan to integrate its distribution operati
-
Bora Pharmaceuticals Completes Health Canada Inspection
contractpharma
April 25, 2021
Mississauga site is the company’s first manufacturing facility in North America and is its HQ in the region.
-
Bora Adds Four Business Development Directors
contractpharma
July 24, 2020
Bora Pharmaceuticals, a full-service contract development and manufacturing organization (CDMO) which specializes in immediate and modified release tablets and capsules, along with serialized packaging, has appointed four business development directors..
-
Bora Secures FDA Approval for CDMO Services
contractpharma
September 04, 2019
Bora, a contract development and manufacturing organization (CDMO) that specializes in modified release (MR) and solvent production, has reported a successful FDA general inspection for its facility in Zhunan...